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the osteogenic commitment 
of CD271+CD56+ bone 
marrow stromal cells (BMScs) 
in osteoarthritic femoral head bone
Dragos c. ilas1, Thomas G. Baboolal1,2, Sarah M. churchman1, William G. Jones1,3, 
peter V. Giannoudis1, Hans‑Jörg Bühring4, Dennis McGonagle1,2 & elena Jones1*
Osteoarthritis (OA), the most common joint disorder, is characterised by progressive structural 
changes in both the cartilage and the underlying subchondral bone. In late disease stages, 
subchondral bone sclerosis has been linked to heightened osteogenic commitment of bone marrow 
stromal cells (BMSCs). This study utilised cell sorting and immunohistochemistry to identify a 
phenotypically-distinct, osteogenically-committed BMSC subset in human OA trabecular bone. 
Femoral head trabecular bone tissue digests were sorted into CD45-CD271+CD56+CD146-, CD45-
CD271+CD56-CD146+ and CD45-CD271+CD56-CD146-(termed double-negative, DN) subsets, and 
CD45+CD271-hematopoietic-lineage cells served as control. Compared to the CD146+ subset, the 
CD56+ subset possessed a lower-level expression of adipocyte-associated genes and significantly 
over 100-fold higher-level expression of many osteoblast-related genes including osteopontin and 
osteocalcin, whilst the DN subset presented a transcriptionally ‘intermediate’ BMSC population. All 
subsets were tri-potential following culture-expansion and were present in control non-OA trabecular 
bone. However, while in non-OA bone CD56+ cells only localised on the bone surface, in OA bone they 
were additionally present in the areas of new bone formation rich in osteoblasts and newly-embedded 
osteocytes. In summary, this study reveals a distinct osteogenically-committed CD271+CD56+ BMSC 
subset and implicates it in subchondral bone sclerosis in hip OA. CD271+CD56+ subset may represent a 
future therapeutic target for OA and other bone-associated pathologies.
Osteoarthritis (OA) is now recognised as a disease of the whole joint characterised by pathological changes to 
cartilage, subchondral bone and the  synovium1,2. While the site of initiation is still unclear, subchondral bone 
changes are an important feature in OA  pathophysiology3. Given the high numbers of bone marrow stromal cells 
(BMSCs) in the subchondral  bone4–6, their homeostatic role in health, as well as their potential contribution to the 
endogenous repair mechanisms in OA is currently an area of considerable interest. Recent studies in OA animal 
 models7 and in human  OA8,9 point towards an altered commitment of BMSCs in OA progression. BMSCs have 
been long described as a heterogeneous population of  cells10,11 however, no specific markers capable of identify-
ing and segregating differently-committed BMSC subsets in healthy or OA-affected bone have so far been found.
Currently, CD271 is considered as one of the characteristic markers for native human  BMSC12–15. We have 
previously shown an accumulation of CD271+ BMSCs in the damaged femoral head areas of hip OA patients 
marked by the presence of bone marrow  lesions8, which are also known to be associated with cartilage loss 
and bone  sclerosis16. More recently, we have provided further evidence for increased osteogenic activity in OA 
subchondral bone, implicating both BMSCs and their terminally differentiated progeny osteocytes in hip OA 
microstructural  changes9. Specifically, the CD271+ BMSCs were found to accumulate in areas of bone sclerosis 
and to reside in direct proximity to osteoblasts and immature osteocytes. Additionally, their gene expression pro-
file indicated a predilection for bone formation as evident by the elevated levels of numerous osteogenic-lineage 
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molecules as well as the early osteocyte marker,  E119. Therefore, we hypothesised that a distinct osteogenically-
committed BMSC subset could be found in human trabecular bone and be elevated in OA femoral head bone.
In a pioneering study by Tormin et al., healthy CD271+ BMSCs were segregated into bone-lining and perivas-
cular subsets, the latter marked by the presence of CD146, also known as melanoma-cell adhesion  molecule17. 
CD146 has been earlier proposed as a marker of perivascular progenitors in many tissues, which allow these 
cells to gain easy access to wider tissue area if repair is  needed18,19. The phenotypic and functional identity of 
the bone-lining subset of CD271+ BMSCs remained however less  explored17. CD56, also known as neural cell 
adhesion molecule, has been previously shown to be expressed on a small subset of CD271+ BMSCs aspirated 
from healthy bone  marrow20,21. More recently, CD56 was documented to co-localise with CD271 on the surface 
of both healthy and OA trabecular bone, but not be present in the perivascular  regions22. At this bone-lining 
location, CD56 expression was independently documented not only in a flat thin cell layer of  cells23, but also 
in active osteoblasts that coincided with their deposition of collagen I and alkaline phosphatase  activity24. In 
accumulation, this indicated that CD56 could be acquired by BMSCs as they progressed along the osteogenic 
lineage, and could, therefore, be a potential marker of osteogenically-committed BMSCs. Given the accelerated 
bone remodelling and sclerosis that is characteristic of OA, it could be predicted that such a BMSC subset might 
be increased at this location.
The aims of this study were therefore to investigate the presence of CD271+CD56+ BMSCs in OA bone, and 
to test their gene expression for further elucidation of their potential contribution to OA associated bone changes.
Results
Gene expression profile of CD271+ BMSC subsets  in OA femoral head trabecular bone.  To 
investigate the existence of phenotypically distinct BMSC subsets in OA trabecular bone, enzymatically extracted 
cells were processed for cell sorting and the BMSCs were gated based on the CD45-CD271+ phenotype while the 
CD45+CD271- hematopoietic-lineage cells (HLCs) were used as a negative non-BMSC control, as previously 
 described25–27 (Fig. 1a). In all samples, non-overlapping subsets of cells CD271+CD56+ (abbreviated CD56+) 
and CD271+CD146+ cells (abbreviated CD146+) were found while the majority of the CD45-CD271+ BMSC 
population lacked both CD56 and CD146 and was termed the double negative (DN) subset (Fig. 1a).
All three CD271+ BMSC subsets were next sorted from OA femoral head trabecular bone digests for down-
stream gene expression analysis. Sorting gates were set as shown on Fig. 1a and a panel of 96 genes was used, 
summarised in Supplementary Table 1, to include transcription factors (TFs) and mature proteins involved in 
BMSC osteogenic, adipogenic and chondrogenic differentiation, as well as selected molecules shown to be highly 
expressed in in vivo CD45-CD271+ BMSCs from previous microarray and gene expression  studies17,26,28,29. The 
gene expression results were subjected to hierarchical  clustering26, and showed a clear separation of all three 
BMSC subsets away from the HLCs, as expected (Fig. 1b). Furthermore, within the CD271+ BMSC population, 
CD56+ and CD146+ subsets clustered away from each other whilst the DN subset was positioned in-between, 
potentially suggesting its transitional nature.
The statistical analysis of individual genes expression in the three subsets revealed that out of 94 tested genes, 
20 of them were expressed > twofold higher in the CD56+ subset compared to CD146+ subset (Table 1). The most 
differentially expressed genes (showing > 100 fold differences in their expression) were the genes encoding two 
mature bone proteins osteopontin (SPP1, 508-fold, p = 0.0016) and osteocalcin (BGLAP, 163-fold, p = 0.0045), 
the latter also present on active  osteoblasts30, as well as chondroadherin (CHAD), which is involved in both 
osteogenesis and  chondrogenesis31 (221-fold, p = 0.0045) (Fig. 1c). The level of OMD, encoding osteomodulin, 
an extracellular matrix protein with important roles in osteoblasts formation and  mineralisation32 was 86-fold 
higher (p = 0.0047) in the CD56+ compared to CD146+ subset (Fig. 1c).
The complete list of differentially expressed molecules between CD56+ and CD146+ subsets is shown in 
Table 1 and also includes osteogenic TF SP7 (osterix) and many molecules belonging to Wnt and BMP signalling 
pathways. Of note, for the majority of these differentially expressed genes, their average expression in the DN 
subset was intermediate between the CD56+ and CD146+ subsets (Fig. 1c).
The only gene that was found significantly lower in CD56+ subset compared to CD146+ cells was TF PPARγ 
commonly associated with adipogenesis (2.6-fold, p = 0.0133) (Fig. 1d). Interestingly, the expression of FABP4, 
encoding a mature adipocyte protein (fatty acid-binding protein 4) was lower in both CD56+ and DN cells com-
pared to CD146+ cells (12- and 16-fold, respectively) however, the differences only reached statistical significance 
Figure 1.  Gene expression profile of CD56+ BMSC subset in OA femoral head trabecular bone. (a) Cell 
sorting strategy based on the identification of CD45-CD271+ BMSCs and negative control CD45+CD271- 
HLCs followed by the separation of BMSCs into the three distinct subsets: CD56+ (CD45-CD271+CD56+), 
CD146+ (CD45-CD271+CD146+) and DN (CD45-CD271+CD56-CD146-) (proportion of each subpopulation 
is presented as mean ± SD, n = 23 donors). (b) Dendrogram showing hierarchical cluster analysis of the BMSCs 
subsets and HLCs gene expression from OA trabecular bone; the colour scale reflects the log transformed fold 
differences relative to HPRT1; grey—missing data (below detection). (c) Osteogenesis-related genes expressed 
at significantly higher levels in CD56+ subset compared to CD146+ subset. (d) Genes expressed at lower levels 
in CD56+ subset compared to CD146+ subset. (e) Chondrogenesis associated genes and CXCL12. Data are 
represented as bar graphs (means) with standard deviations (error bars) for donor-matched samples and gene 
expression values are relative to HPRT1 on a log scale. LD: low detection; * < 0.05, ** < 0.01, Friedman test for 
the donor matched samples corrected with the Bonferroni–Dunn multiple-group comparison. While n = 6 
donor samples were analysed, only n = 5 had complete datasets for all the sorted subsets to be presented in the 
dendrogram (b). However, where present the genes with 6 matching data points are shown for full transparency 
of acquired data (c–e).
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for the DN subset (p = 0.0140). Finally, another gene that was significantly lower in DN subset compared to 
CD146+ subset (sixfold, p = 0.0159) (Fig. 1d) and importantly below detection in CD56+ subset, was GATA2, 
a TF initially described as specific for haematopoietic stem  cells33, but subsequently shown to have a role in the 
differentiation of  BMSCs34.
While some genes associated with BMSC chondrogenesis (SOX9, PRELP encoding prolargin and COMP 
encoding cartilage oligomeric matrix protein) showed higher expression levels in both CD56+ and DN subsets 
compared to CD146+ subset, they didn’t show a trend for higher-level expression in the CD56+ subset compared 
to the DN subset (Fig. 1e). Finally, CXCL12, encoding a well-known stromal support chemokine SDF-135, showed 
markedly higher expression in DN cells compared to both CD56+ (sevenfold, p = 0.0133) and CD146+ (fourfold) 
subsets (Fig. 1e), although the latter was not statistically significant.
Taken together, this gene expression analysis revealed distinct transcriptional profiles of CD56+, DN and 
CD146+ BMSC subsets in OA femoral head bone, and an increased osteochondral commitment from the 
CD146+ subset to DN and CD56+ subsets, followed by an increased osteogenic commitment from the DN to 
the CD56+ subset.
Multipotentiality and distinct morphology of the CD56+ BMSC subset in OA femoral head tra‑
becular bone.  We next investigated the morphological characteristics and the multipotentiality of the puri-
fied BMSC subsets in vitro. Cells were sorted as indicated on Fig. 1a, and placed in BMSC culture media for the 
analysis of their morphology, motility and formation of tripotential cultures (Fig. 2).
Firstly, a notable morphological difference was observed between the CD56+ subset and the other two subsets 
(CD146+ and DN) following their attachment to plastic (1 day after sorting). The CD56+ subset displayed a circu-
lar shape, while the DN and CD146+ cells displayed a spindle shape cell morphology (Fig. 2a). This was assumed 
to be related to inherent cell motility and confirmed by measurements of cell circularity, where 0 represented a 
straight line and 1 represented a perfect  circle36. The average circularity of the cells from the CD56+ subset was 
close to 1 (median 0.823, range 0.652–0.933), while the DN and CD146+ cells were significantly more elongated 
(median 0.398, range 0.209–0.644 and median 0.301, range 0.122–0.635, respectively). However, these distinct 
features were not maintained in culture, and by day 7 all the subsets adopted a spindle-shape morphology and 
displayed similar heterogeneity in their rates of motility (Fig. 2b).
Upon reaching the first passage, cells from all the three subsets were subjected to osteogenic, adipogenic and 
chondrogenic induction in standard trilineage differentiation  assays37 (Fig. 2c). Culture-expanded cells from all 
three subsets responded well to osteogenic, adipogenic and chondrogenic induction, and no particular differences 
Table 1.  Genes differentially expressed between CD56+ and CD146+ BMSC subsets from OA femoral head 
bone. * Friedman test for the donor matched samples with the Bonferroni–Dunn correction for multiple-group 
comparisons. BD below detection, NA not available.
Gene symbol Gene name Fold difference p value*
SPP1 Secreted phosphoprotein 1 (osteopontin) 508.62 0.0045
CHAD Chondroadherin 221.22 0.0045
BGLAP Bone gamma-carboxyglutamate protein (osteocalcin) 163.11 0.0016
OMD Osteomodulin 86.02 0.0047
WIF1 WNT inhibitory factor 1 80.85 0.0045
SFRP4 Secreted frizzled-related protein 4 40.36 0.0133
SP7 Sp7 transcription factor 25.78 0.0140
TNFRSF11B Tumour necrosis factor receptor superfamily, member 11b (osteoprotegerin) 15.53 0.0342
RUNX2 Runt-related transcription factor 2 13.57 0.0117
BAMBI BMP and activin membrane-bound inhibitor homolog 11.75 0.0133
PDGFRA Platelet-derived growth factor receptor, alpha polypeptide 10.31 0.0342
FGFR3 Fibroblast growth factor receptor 3 8.12 0.0047
CDH11 Cadherin 11, type 2, OB-cadherin 6.93 0.0342
TWIST1 Twist homolog 1 6.91 0.0133
BMPR1A Bone morphogenetic protein receptor, type IA 6.20 0.0047
FZD8 Frizzled homolog 8 6.01 0.0342
FGFR1 Fibroblast growth factor receptor 1 5.07 0.0047
NOG Noggin 3.82 0.0047
FZD7 Frizzled homolog 7 3.62 0.0133
ALPL Alkaline phosphatase 2.78 0.0342
PPARG Peroxisome proliferator-activated receptor gamma 0.38 0.0133
GATA2 GATA binding protein 2 BD in CD56 NA
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in their ALP activity or calcium deposition were noted on day 21 post-osteogenic induction (Fig. 2c). A slight 
trend for a more adipogenic response was noted in the CD146+ subset compared to the other two subsets based 
on day-21 Nile red/DAPI fluorescence quantification (Supplementary Fig. 1a). This was also observed by qPCR 
by measuring transcripts specific to adipogenic lineage cells, PPARγ and FABP4 (Fig. 2c, bottom panel). While all 
subsets responded to adipogenic induction by increasing the levels of these transcripts, the fold-changes between 
Day 0 and Day 21 post-induction were notably higher in the CD146 subset, especially for FABP4 (average 2000-
fold) while in CD56+ and DN subsets its levels were elevated on average 100-fold and 70-fold, respectively 
(Fig. 2c, bottom panel). The diameter measurements of the chondrogenic pellets on day 21 post-chondrogenic 
induction (Fig. 2c) showed a lower diameter of the CD146+ subset, but no significant differences were observed 
between the BMSC subsets in the sGAG levels (Supplementary Fig. 1a). Similar day-21 levels of selected lineage-
specific transcripts were found by qPCR for osteogenesis while chondrogenesis-related transcripts were notably 
below detection in the CD146+ subset and the highest in the CD56+ subset (Supplementary Fig. 1b).
Altogether, these data showed that all three sorted subsets were multipotential following adherence to plastic 
and standard culture, confirming their BMSC identity. However, their native gene expression and morphological 
traits were not faithfully preserved in culture, confirming previous  reports26,28 and highlighting the limitation of 
using cultured BMSCs for the analysis of BMSC heterogeneity in vivo.
The topography and quantification of CD56+ cells  in OA and control  trabecular bone.  The 
topographical distribution of CD271- and CD56-expressing cells was next investigated in OA femoral head 
trabecular bone and control iliac crest (IC) trabecular bone and femoral head trabecular bone from the neck of 
femur fracture (NFF) patients (Fig. 3). In control IC bone, the expression of CD56 was limited to a thin layer 
of cells lining the trabecular surface in a similar location as that of CD271 expressing cells (Fig. 3a). In femoral 
head bone from OA patients, two patterns of CD56 expression were found depending on the proximity of bone 
to damaged cartilage areas. In deep femoral head areas not visibly affected by OA, CD56+ cells formed a single 
layer of bone-lining cells, similar to control bone (Fig. 3b, left panel). However, in the subchondral areas showing 
active bone remodelling signs, with a characteristic presence of osteoblasts and osteoclasts, CD56 was present on 
multiple layers of cells proximal to bone, as well as on some osteoblasts (Fig. 3c, left panel). In NFF bone, CD56 
was limited to the cells present on the bone surface (Fig. 3d, left panel). Co-localisation of CD271 and CD56 on 
bone-lining cells, as well as the presence of single marker-positive cells in OA subchondral bone was confirmed 
by dual staining immunofluorescence (Fig. 3e). In all samples, CD271+ cells were more numerous compared to 
CD56+ cells and in addition to the cells lining the bone, included the stromal cells present inside the bone cavi-
ties and around blood vessels (Fig. 3a–d, right panels and e).
The proportions of CD271+CD56+ cells, as well as other BMSC subsets, were next quantified in bone enzy-
matic digests using flow cytometry (Fig. 3f). In relation to total live cells, the whole fraction of CD45-CD271+ 
BMSCs was the highest in OA bone (6- and 11-fold higher compared to IC and NFF bone, p = 0.0168 and 
p = 0.0021, respectively), with the same pattern seen for the CD146+ and DN BMSC subsets (Fig. 3f). The CD56+ 
subset was similar in proportion in OA and NFF enzymatic digests, and higher than in IC bone digests (20-fold 
higher for both, p = 0.0002 and p = 0.0483, respectively).
Confirmation of  the CD56+ subset  involvement  in new bone  formation  in OA.  An apparent 
increase in CD56+ cells in the subchondral bone remodelling areas, its notable pro-osteogenic gene expression 
and the presence on some osteoblasts in OA trabecular bone suggested that CD56+ BMSCs could be directly 
involved in subchondral trabeculae thickening and reorganisation in  OA38.
To address this, OA bone sections were first stained with Picrosirius red (PSR), a dye useful for revealing 
the collagen organization and fibre orientation in connective tissues (Fig. 4a)39. Multiple layers of CD56+ cells 
were present adjacent to bone areas of bright red collagen staining that also contained high density of embedded 
osteocytes (Fig. 4a, left and middle panels). Under a polarised light, the differences in collagen fibres’ organisation 
adjacent to the bone surface and inside the bone became more striking, and the bone areas where CD56+ and 
recently embedded osteocytes co-localised, were stained red while the remaining bone appeared yellow-to-green, 
indicating differing degrees of collagen organisation consequent to its maturity.
To investigate whether CD56+ cell accumulation was indeed associated with newly-formed, immature bone 
tissue (Fig. 4a, right panel), consecutive femoral head OA bone sections were next stained with antibodies against 
CD271, CD56 and E11, a marker for young, immature  osteocytes40. The staining revealed the presence of CD56+ 
cells including some osteoblasts in a direct proximity bone containing high densities of E11+ immature osteocytes 
(Fig. 4b, left and middle panels). CD271+ cells were more broadly distributed, as expected, but notably excluded 
osteoblasts (Fig. 4b, right panel). The direct proximity of CD56+ cells and immature osteocytes was even more 
apparent on a transverse section across the top of the growing trabeculae (Fig. 4c). This staining pattern indicated 
the osteogenic (i.e. bone-forming) potential of the CD56+ BMSC subset in OA bone.
CD56 staining was next quantified in large sections of femoral heads in relation to the degree of bone scle-
rosis, as previously  described9. The areas of interest were traced selecting out the bone and cavity areas followed 
by calculating the percentage of CD56 positive area in relation to total cavity area (Supplementary Fig. 2). The 
analysis revealed that the CD56 positive areas were significantly increased in the sclerotic areas of femoral heads 
(defined as having bone area representing more than 60% of the total  area9) in comparison to donor matched 
non-sclerotic areas. Based on median values, the CD56+ cell presence was 5.8-fold higher in the sclerotic areas 
(p < 0.0001) compared to the non-sclerotic areas (Fig. 4d, left panel). When quantification of CD56+ cells was 
repeated to exclude the osteoblasts, the same trend for higher CD56 positivity in the sclerotic areas (3.5-fold 
6
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:11145  | https://doi.org/10.1038/s41598-020-67998-0
www.nature.com/scientificreports/
7
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:11145  | https://doi.org/10.1038/s41598-020-67998-0
www.nature.com/scientificreports/
higher, p < 0.0001) was evident (Fig. 4d, right panel). This suggests that CD56+ cells actively contributed to bone 
formation activity in OA.
Discussion
An increase in the subchondral bone volume is a characteristic feature of late-stage  OA41–43 and has been pre-
viously linked to a preferential BMSC commitment towards osteogenesis in both  animals7 and  humans9. The 
current study has identified a BMSC subset with a characteristic CD271+CD56+ phenotype that directly medi-
ates an enhanced osteogenic activity in OA bone. Whereas previous studies have focussed on the perivascular 
CD271+CD146+  BMSCs17, this is the first study to demonstrate a distinct identity of the CD271+CD56+ BMSC 
subset in human bone and to directly compare their gene expression with the CD271+CD146+ perivascular 
BMSCs. Our data suggest that the loss of surface CD146 marks a gradual transition of BMSCs towards osteochon-
drogenesis, whereas a gain of CD56 marks a further osteogenic commitment step, which ultimately manifests 
itself as an accumulation of osteoblasts and immature osteocytes in CD56 cell-rich areas of OA bone. In a recent 
study, magnetically-sorted CD146+ cells from the rat growth plate exhibited high chondrogenic differentiation 
capacity in vitro, compared to CD105+  cells44. Their seemingly different results to our work could be explained 
by studying different species (human versus rat), tissue sources (trabecular bone versus the growth plate) and 
control subpopulations (CD56+ versus CD105+).
In the present study, the multipotential nature of the CD56+ BMSC subset was demonstrated following 
stringent FACS-based purification followed by in vitro tri-lineage differentiation assays. Their remarkable osteo-
genic commitment, in their native state, was studied without any culture-expansion and was evidenced by the 
increased expression of a vast array of bone formation associated genes including SPP1 (osteopontin) and BGLAP 
(osteocalcin), two major components of bone extracellular  matrix30, and OMD (osteomodulin), a proteoglycan 
previously proposed as an organiser of bone mineral  formation45 as well as regulator of type I collagen fibril 
 diameter46. Compared to CD146+ BMSCs, CD56+ BMSCs also expressed higher levels of SOX9, a chief chon-
drogenic transcription factor, as well COMP (cartilage oligomeric matrix protein), however, the fold-differences 
were not as striking as those noted for the osteogenic molecules. On the other hand, adipogenesis- and stromal 
support related molecules were lower expressed in the CD56+ BMSCs, likely due to their downregulation as a 
result of the CD56+ cell osteogenic commitment. This provided the first demonstration of the intrinsic differences 
in the lineage commitment between the two phenotypically-distinct BMSC subsets in human bone. In vitro dif-
ferentiation assays that we have used are however prone to artifact and the gold standard in vivo transplantation 
of these cells would be required to unequivocally document their  multipotency17,29.
Previous studies have reported on the existence of CD56+ and CD146+ BMSC subsets in human bone 
 marrow17,21,47, but the combined use of these markers has never been used before. In this study, their combined 
use on bone tissue digests facilitated the identification of a third, double-negative (DN) CD271+ BMSC subset 
in human bone, which was characterised by the higher-level CXCL12 transcript  expression48. This DN subset 
was not specific to OA bone and was also present in both IC and NFF bone but at a lower frequency. Its native 
gene expression signature suggested its transitional ‘osteochondral’ nature, with a lower adipogenic transcript 
expression compared to the CD271+CD146+ subset, and lower osteogenic transcript expression compared to the 
CD271+CD56+ subset. Therefore, it may represent a human equivalent to ‘osteoblast/chondrocyte progenitors’ 
recently identified in mouse bone marrow using a single-cell RNA sequencing  technology11. Given the major 
role of CXCL12 in cell  migration35,49,50, this DN BMSC subset may facilitate the migration and re-location of 
BMSCs from blood vessels to the bone formation or remodelling areas, a process believed to be exaggerated in 
OA-affected  bone51.
In our recent study, we used BMSC culture-expansion to demonstrate that cell isolates with a higher per-
centage of CD271+CD56+ BMSCs, obtained after rasping of the femoral canal of OA patients, produced more 
chondrogenic BMSC cultures compared to donor-matched IC  aspirates22. In contrast to the present work, the 
DN subset was not quantified in our previous study, but given its proportion, could have also contributed to the 
high levels of chondrogenesis observed in these isolates. In accumulation, both sets of data on CD271+CD56+ 
Figure 2.  Morphological and migratory characteristics of BMSC subsets in early culture and their 
multipotentiality following standard culture-expansion. (a) Morphological analysis of the CD56+, DN and 
CD146+ BMSC subsets 24 h after FACS purification. Left: representative cells, right: graph showing the cell 
circularity calculated using ImageJ (a total of n = 30 cells in each subset from n = 5 OA donors). **** < 0.0001, 
Kruskal–Wallis test. (b) Cell motility calculated based on the total distance (μm) travelled by individual cells 
over the course of 6 h, each line representing a single cell over time. (c) Representative images showing tri-
lineage differentiation potentials of CD56+, DN and CD146+ BMSC subsets, all assays were performed in 
triplicate wells/pellets from each of n = 3 OA donors. Osteogenic differentiation was assessed by ALP staining 
(blue) on day 14 post-osteogenic induction with visible mineralising nodules (dark spots) and by alizarin red 
staining (red) on day 21. Chondrogenic differentiation was assessed by generating chondrogenic pellets (bar 
indicating 2 mm) and toluidine blue staining of glycosaminoglycans in the pellet cultures (both on day 21). 
Higher magnification images show substantial extracellular matrix deposition and bona fide chondrocytes 
lying in lacunae within the pellets (indicated by arrows). Adipogenic differentiation was visualised by oil-red-O 
staining of lipid vacuoles and by transcriptional analysis of adipogenic transcripts PPARG and FABP4 on day 21 
post-induction; the data are presented as donor-matched connecting lines in n = 3 donors. Images were taken 
using Epson scanner for low magnification (ALP- and AR-stained plates and whole chondrogenic pellets) and 
using Nikon camera attached to Nikon microscope for microphotographs (osteogenesis: × 20, chondrogenesis: 
× 20 and × 40 (toluidine blue sections), adipogenesis: × 20.
◂
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Figure 3.  The topography (a–e) and quantification (f) of CD271+CD56+ BMSC subset in osteoarthritic and 
control trabecular bone. Representative adjacent sections (5 μm) stained with antibodies against CD56 and 
CD271. (a) Heathy iliac crest, (b) Deep area of trabecular bone in OA femoral head, (c) subchondral area with 
active bone remodelling area of OA femoral head and (d) subchondral area of NFF femoral head. Arrows: 
bone lining location of CD56+ and CD271+ cells, arrow heads: osteoblasts, white arrows: osteoclasts. Scale 
bar 100 μm. (e) immunofluorescence double-staining of subchondral area of OA femoral head for CD271 
(green) and CD56 (red) indicating their co-expression on the cells at the bone surface (yellow); blue: nuclear 
staining using DAPI; Scale bar 50 μm. (f) Quantification of native CD45-CD271+ BMSCs extracted from 
trabecular bone of OA donors (N = 23) in comparison to healthy IC (N = 11) and NFF (N = 6) trabecular bone. 
Graphs presented as dot plots show the percentages of CD45-CD271+ BMSCs in total live cells as well as the 
percentages of each of the CD271+ BMSC subset in total live cells. Each dot represents one donor. * < 0.05, 
*** < 0.001, Kruskal–Wallis test.
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BMSCs indicate their BMSC nature, a high state of ‘readiness’ for osteochondral differentiation, and their further 
commitment to osteogenesis in bone affected by OA.
The fact that CD56+ BMSCs appear to directly contribute to bone formation in OA-affected bone was next 
documented in this study using histology and immunohistochemistry. In control non-OA bone, as well as in 
OA femoral head areas distant to cartilage damage, the CD271+CD56+ BMSCs were restricted to the bone lin-
ing region, while the remaining CD271+ BMSCs located within the stromal architecture and around the blood 
vessels. In OA-affected bone though, characterised by the active remodelling signs and significantly thickened 
 trabeculae9, CD56+ cells were additionally increased in the vicinity of osteoblasts, osteocytes and immature 
collagen fibrils. Furthermore, osteocytes neighbouring these CD56+ cells were also immature as shown by their 
morphology and the expression of an early-osteocyte marker  E119. CD56 expression was also maintained in some 
neighbouring multi-layered stromal cells believed to be pre-osteoblasts as well as cuboidal osteoblasts, which were 
notably negative for CD271. This supported early studies showing that CD56 could be a transient molecule during 
osteoblast differentiation in skeletal  morphogenesis24, and indicating their in situ osteogenic  commitment23,52.
The current evidence on the origin of osteoblasts remains unclear. While some studies indicate that quiescent 
bone lining cells represent a major source of osteoblasts during  adulthood53–55, others propose the recruitment/
migration of osteoprogenitors from ‘canopy cells’ reported to cover most bone remodelling sites, or from nearby 
blood  vessels53,54. Data presented in this study demonstrate the presence of CD271 and CD56 on both the qui-
escent bone surfaces (in non-OA bone) and on active bone surfaces (in OA-affected bone). Given that these 
CD56+ cells were found to be highly osteogenically-committed, our study indicates that a remote recruitment 
Figure 4.  CD56+ subset involvement in new bone formation in OA. (a) Co-localisation of CD56+ cells (left 
panel) with the areas of new bone formation indicated by picrosirius red staining visualised under bright field 
microscopy (middle panel) and polarised light microscopy (right panel); rectangles: areas of interest for CD56+ 
cells activity. (b) and (c) Representative adjacent sections from the areas of bone sclerosis. Co-localisation of 
CD56+ cells (left panel) with immature E11+ osteocytes (middle panel) in comparison to the whole population 
of CD271+ BMSCs (right panel); (b) sagittal section, (c) transverse section (through growing trabeculae). (d) 
Graph showing the area of CD56 positivity as percentage of total cavity area (multiple measurements from n = 4 
femoral heads). White box: non-sclerotic areas of femoral heads; grey box: sclerotic areas; w/o OBs: without 
osteoblasts. **** < 0.0001, Kruskal–Wallis test. Arrows: bone lining location of CD56+ and CD271+ cells, 
arrowheads: osteoblasts, empty arrowheads: E11+ osteocytes. Scale bars 100 μm.
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of osteoprogenitors from blood vessels to form new osteoblasts in OA bone may not be necessary. The triggers 
of CD56+ bone lining cell activation in OA may be linked to mechanical loading and osteoclast-induced release 
of excess TGF-β from the extracellular  matrix7, and remain to be further elucidated. This knowledge could help 
to develop new therapeutic strategies for the activation of these CD56+ bone-lining cells in osteoporosis and 
other diseases of bone loss.
This study is limited by the lack of age-matching between OA and IC bone donors and by low numbers of 
CD271-positive BMSCs that could be obtained from non-OA trabecular bone (both IC and NFF). Compared to 
OA bone, all BMSC subsets were considerably reduced in numbers in control non-OA bone, which precluded 
their gene expression analysis. A more sensitive and specific approach, such as a single-cell RNA  sequencing11, 
would be necessary to obtain a gene expression profile of these subsets from their healthy environment, as well 
as other bone-associated pathologies such as osteoporosis. Additionally, new three-dimensional assays for testing 
BMSC subsets’ functionality such as a mesosphere  assay29, would need to be standardised and validated. Meso-
sphere assay is useful not only because it can serially measure the clonogenic cell content of the sorted population 
in vitro, but also because these spheres can be subcutaneously implanted into immunodeficient mice to measure 
in vivo self-renewal of these clonogenic  cells29. As seen in this study, as well as many other  studies22,26,28,56,57, 
standard BMSC culture-expansion leads to significant gene and surface marker expression changes in BMSC 
subsets and hence there is a growing need for other methods to study native BMSC functional properties and 
differentiation potentials. It will be very valuable to assess colony forming efficiency of the three different BMSC 
subsets at clonal density before and after FACS, as the latter can cause a significant loss of BMSCs, and these 
losses may be unequal across the three subsets. Stable labelling of the subsets with different chromophores and 
looking at the percentages of chromophore-positive colonies out of total colonies, as in lineage-tracking experi-
ments in animal  models58–60, would be needed to establish their colony-forming efficiency. Ultimately, the in vivo 
transplantation into an appropriate tissue environment would be required to assess the clonogenicity and lineage 
commitment of the sorted cell subsets in their more natural  states17,60–63.
In summary, this is the first study where the CD271+ BMSCs were dissected into different subsets and com-
pared between each other in OA bone, revealing their distinct phenotypes and gene expression signatures in their 
native states and avoiding in vitro manipulations that lead to significant changes in gene expression. Identifying 
and characterising CD271+CD56+ osteoprogenitor cell subset in OA bone provides novel insights into the OA 
bone remodelling process and potential novel approaches for bone manipulation in OA therapy  development64. 
For example, the bone-lining location of CD271+CD56+ BMSCs may facilitate the development of novel bio-
logics and small molecules allowing to target these cells similarly to bisphosphonates in order to re-establish 
the normal bone turnover. A better knowledge on BMSC subsets in bone could be also useful for new therapy 
development in diseases associated with an abnormal bone-forming phenotype, such as spondyloarthropathies, 
or conditions where bone formation is lacking, such as osteoporosis.
Methods
Patient samples and bone tissue processing.  All patients gave informed consent and this study was 
undertaken after approval from the Leeds East and Leeds West Research Ethics Committees as well as local 
National Health Service Research and Development in compliance with the Helsinki Declaration of ethical 
principles for medical research involving human subjects. For this study a total of N = 34 OA donors (15 males 
and 19 females) with age range between 40 and 90  years (median = 71) were recruited while controls com-
prised of healthy iliac crest (IC) bone (N = 11, 6 males and 5 females) with age range between 38 and 78 years 
(median = 53) and femoral heads from neck of femur fracture (NFF) patients (N = 7, all females) with age range 
between 67 and 93 years (median = 75). No statistical significance in donor age was found between OA and NFF 
groups in contrast to IC donors which were significantly younger (Kruskal–Wallis test).
From all bone samples, BMSCs were extracted by enzymatic digestion and cell sorting as described 
 previously9. Briefly, trabecular bone was first manually segregated from cortical bone, periosteum/endosteum 
and cartilage using sterile surgical instruments (scalpel and rongeur) (Supplementary Fig. 3). The trabecular 
bone samples were then broken down into small fragments (< 1 g) using a 22 cm Stille-Luer bone rongeur and 
extensively washed with phosphate buffered saline (PBS, Sigma, UK) to remove fat and haematopoietic cells. 
Trabecular bone fragments were then subjected to 4 h’ incubation at 37 °C with 0.22% collagenase (Worthing-
ton Biochemical, USA) (corresponding to 3000 U/g of bone). Following digestion, the collagenase solution was 
separated from the remaining bone by filtering through a 70 µm cell strainer (BD Biosciences, USA), while the 
bone fragments were washed twice in large volumes of PBS to remove any residual cells. These were pooled with 
the original collagenase solution, centrifuged (300xg for 5 min) and resuspended in DMEM (Thermo Fisher, 
USA) (commonly 15–30 ml), containing 10% foetal calf serum (Biosera, France) and 1% penicillin/streptomycin 
(Thermo Fisher).
BMSC subset isolation using fluorescence-activated cell sorting (FACS).  To enumerate and iso-
late native BMSC subsets, up to  106 of the enzymatically released cells were incubated with 15 µl of fluorescein 
isothiocyanate (FITC)-conjugated CD45 (Agilent Dako, USA), 20 µl allophycocyanin (APC)-conjugated CD271, 
20 μl phycoerythrin (PE)-conjugated CD146 (both from Miltenyi Biotec, Germany) and 10 μl of brilliant violet 
21 (BV21)-conjugated CD56 (Biolegend, USA) for 20 min at room temperature, washed in FACS buffer and cen-
trifuged (5 min at 300×g). Cells were re-suspended in 500 µl FACS buffer, filtered through a 72 μm cell strainer 
cap (Corning Falcon, USA) into a fresh tube to remove any remaining bone debris or cell clumps. To exclude the 
dead cells, 10 µl 7-amino-actinomycin D (7-AAD) (Miltenyi Biotec) was added before the cell sorting procedure. 
Sorting gates were first created by selecting CD45lowCD271+ cells, comprising the BMSC  population6,9, while 
the CD45+CD271- gate was used for the collection of haematopoietic lineage cells (HLCs), which were also 
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analysed as control population for BMSCs. The subsequent isolation of BMSCs subsets was based on the gates 
for CD56 and CD146 positive cells set using the corresponding isotype control antibodies (Fig. 1a). A CD271+ 
subset negative for both CD146 and CD56, the double-negative (DN) subset, was also collected. In general, an 
average of 3 × 103 cells (range 0.5 × 103–1.5 × 104 cells) of CD56+ cells, the rarest BMSC subset, were collected 
using a BD Influx cell sorter (BD Biosciences). Sort-purified BMSC subsets and HLCs were collected directly 
into 100 μl of RNA lysis buffer (Norgen Biotek, Canada) for downstream gene expression analysis.
Gene expression.  Total RNA from FACS-purified BMSC subsets and control HLCs was extracted using 
the Single Cell RNA Extraction kit (Norgen Biotek) following manufacturer’s protocol and on-column DNase 
I treated (Applied Biosystems, USA). Total RNA was then quantified and used to synthesize first-strand cDNA 
using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to manufacturer’s 
instructions. qPCR was performed on a QuantStudio 7 Flex Real-Time PCR System (Applied Biosystems) using 
TaqMan Low Density Array (TLDA) cards in 96a format (Thermo Fisher), designed using exon spanning assays 
wherever possible, the full list of transcripts presented in Supplementary Table 1. Gene expression levels were 
normalised relative to housekeeping gene HPRT1 then calculated using the  2−ΔCt method.
Gene expression analysis for major lineage transcripts (RUNX2 and BGLAP for osteogenesis, PPARG and 
FABP4 for adipogenesis and SOX9 and COL2A1 for chondrogenesis) was also performed on Day 21 differentiated 
cells from N = 3 OA donors following differentiation induction, as previously  described37,65.
Cell motility and differentiation assays.  Following cell sorting, the BMSC subsets were placed in cul-
ture in StemMACS media for subsequent expansion and in vitro functional assays. For morphological assess-
ment, images of individual cells from each subset were taken at 24 h after sorting and cell circularity was calcu-
lated using ImageJ software (version 1.8.0_172 National Institutes of Health, USA available at https ://image j.nih.
gov/ij/) using the formula for circularity (4π(area/perimeter2) where 0 represented a straight line and 1 repre-
sented a perfect  circle36. Separate experiments were then performed for cell motility analysis. For this, freshly-
sorted BMSC subsets from N = 4 OA donors were seeded in a 24 well Ibidi culture plates (Ibidi, Germany) at 
the seeding density of 1 × 104 cells/cm2 in 2 ml of StemMACS media and allowed to expand over one week. The 
cell attachment, spreading and movement were then tracked using Holomonitor M4 microscope (Phase Holo-
graphic Imaging AB, Sweden). After automatic calibration of the background and microscope objective, one 
field of each sample was focused on by the digital autofocus feature. The cells were then imaged with photo cap-
tures every 30 min for 24 h. For the evaluation, at each time-lapse sequence, 25 cells were identified and selected 
by minimum error histogram-based threshold algorithm of the software (HoloStudio M4 version 2.6.2 available 
at https ://phiab .com/produ ct/holom onito r-app-suite -softw are). By tracking the cells, the motility of each subset 
was automatically analysed over time, as previously  described66. Genes’ selections were based on our previous 
 studies66–68 as well as other  studies69.
To assess multipotentiality of the sorted subsets, freshly-sorted BMSC subsets (N = 3 donors) were firstly 
seeded in 25 cm2 culture flasks (Corning) and expanded in StemMACS media for one passage to generate suf-
ficient numbers of BMSCs for in vitro differentiation assays. Differentiation was then performed by culturing 
matched BMSC subsets in osteogenic, adipogenic or chondrogenic media (all from Miltenyi Biotec), with media 
changed twice a week, and analysed on day 21, as previously  described37,65.
Histology and immunohistochemistry.  Trabecular bone samples from at least 3 donors were fixed in 
4% paraformaldehyde in a 0.1  M phosphate buffer (pH 7.4) and subsequently decalcified in EDTA (Sigma, 
0.5 M, pH 7.4) at 4  °C. Thereafter, bone tissue was fixed for another 24 h in buffered formalin solution and 
mounted in paraffin blocks for picrosirius red staining and immunohistochemistry (n = 3 sections for each stain 
from each donor).
Immunohistochemistry was employed to evaluate the topography of CD56+ cells in relation to CD271+ 
BMSCs and E11+ immature osteocytes in osteoarthritic and control bone. Decalcified trabecular bone sections 
of 5 μm were deparaffinized in xylene and rehydrated through graded ethanol series. The staining was performed 
using the EnVision+ Dual Link System-HRP (DAB+) (Dako Agilent) kit as previously  described9. Primary anti-
bodies included: CD271 (1:100 dilution, clone NGFR5, Abcam, Cambridge, UK), CD56 (1:300 dilution, clone 
EPR2566, Abcam) and E11 (1:200 dilution, clone NZ1, Merck Millipore, USA). The optimal concentration of 
primary antibodies had been determined in dilution series on test tissue sections (with and without additional 
blocking with casein) and no primary antibody was used as negative control. Non-specific binding of primary 
antibodies was additionally controlled by comparison to a different-specificity antibody of the same species 
origin and isotype, for example anti-Cathepsin K was used as a control for CD56 (both are rabbit polyclonal 
IgG). Slides were scanned on Leica Aperio AT2 and images captured using Aperio Imagescope as previously 
 described9. Quantification was performed using Nuance Multispectral Imaging System (Calliper Life Sciences, 
USA) as percentage of positively stained area within a defined trabecular bone cavity area and region of interest, 
using a minimum of 10 regions per patient as described  previously9.
Immunofluorescence double staining was performed to detect the BMSCs double-positive for CD271 and 
CD56 in OA femoral head bone. The tissue was permeabilised to allow intracellular staining with 0.25% Triton-
X-100 (Sigma) for 15 min at room temperature and blocked using 5% Casein solution (Sigma) for 30 min at 
room temperature before 1 h incubation with the same primary antibodies for CD271 and CD56 used for IHC. 
After 1-h incubation at room temperature, the primary antibodies were washed in Tris buffered saline (Sigma) 
for 5 min and the appropriate conjugated secondary antibodies were added to the tissue sections for 1 h at room 
temperature: Alexa Fluor 488 (1:200, Thermo Fisher) for CD271 and Alexa Fluor 647 (1:200, Abcam) for CD56. 
After washing, the slides were mounted with a coverslip using VectaShield with DAPI (Vector Laboratories, USA). 
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Fluorescence was analysed using a Nikon A1 confocal laser microscope (Nikon) and multiple fluorescent images 
were acquired and presented using NIS Elements software (Nikon). No primary antibody slide was used as con-
trol stained with both secondary antibodies in order to set the threshold and normalise for background signal.
Picrosirius red was used to stain and visualise the collagen fibres in OA femoral heads (n = 4) in order to 
indicate areas of new bone formation. Following dewaxing and rehydration, the slides were incubated for 1 h at 
room temperature in 0.1% PSR solution (Sigma). Next, the slides were briefly washed for 1–2 s in 0.5% acetic 
acid before being mounted with DPX (Leica, UK). The slides were visualised using brightfield as well as polarized 
light microscopy (Nikon) in order to evaluate the size and organization of collagen fibrils of subchondral bone 
in parallel with adjacent slides stained for CD56.
Statistics. The statistical analyses were performed using Friedman test for the donor matched CD271+ 
BMSC subsets (CD56+, DN and CD146+) while Kruskal–Wallis analysis was used for the intergroup differences 
between unmatched data sets, both corrected with the Bonferroni–Dunn multiple-group comparison. Mann–
Whitney test was used for comparisons between two groups. Results are presented as scatter dots plots with 
medians or box and whisker plots, with boxes representing the upper and lower quartiles of the median, and 
whiskers representing the interquartile range, calculated using GraphPad Prism version 7 software. Results were 
considered significantly different at p < 0.05 (with significance level denoted as *p < 0.05, **p < 0.01, ***p < 0.001 
and ****p < 0.001).
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